asundexian

Bayer Reveals Data That Could Make Stroke Prevention Drug Its Next Blockbuster Product

Bayer’s asundexian, a Factor XIa inhibitor, reduced the risk of secondary stroke by 26% without increasing bleeding risk in a Phase 3 clinical trial. The once-daily pill is at the front of an emerging class of medicines that includes drug candidates from Regeneron Pharmaceuticals and partners Bristol Myers Squibb and Johnson & Johnson.

By Frank Vinluan

BioPharma, Pharma

Bayer Falls Short in Bid to Beat Eliquis in Afib, But Key Stroke Study Continues

An independent data monitoring committee concluded Bayer’s experimental drug for atrial fibrillation would not be more effective than Eliquis, a blockbuster product currently used for the indication. Consequently, Bayer decided to stop that Phase 3 test for the once-daily oral small molecule.

By Frank Vinluan